Meeder Asset Management’s BioCryst Pharmaceuticals BCRX Stock Holding History

Meeder Asset Management’s Portfolio BCRX Stock Details BCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-1,015	Closed	-$2K	–	2062
2020 Q1	$2K	Buy	1,015 +416	+69%	+$1.15K	﹤0.01%	2059
2019 Q4	$2K	Buy	+599	New	+$1.51K	﹤0.01%	1990
2019 Q3	–	Sell	-2,214	Closed	-$8K	–	2140
2019 Q2	$8K	Buy	+2,214	New	+$13.3K	﹤0.01%	1513
2019 Q1	–	Sell	-786	Closed	-$6K	–	1700
2018 Q4	$6K	Buy	+786	New	+$6.11K	﹤0.01%	1361
2017 Q3	–	Sell	-156	Closed	-$1K	–	1628
2017 Q2	$1K	Sell	156 -132	-46%	-$804	﹤0.01%	1498
2017 Q1	$2K	Sell	288 -1,280	-82%	-$8.9K	﹤0.01%	1348
2016 Q4	$10K	Buy	+1,568	New	+$8.16K	﹤0.01%	751

Other funds holding BCRX

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Meeder Asset Management's BCRX Position: Q2 2020 in Review

Meeder Asset Management sold out of BioCryst Pharmaceuticals (BCRX) in Q2 2020, closing a stake of 1,015 shares — an estimated $2K sold.

Meeder Asset Management first reported a position in BCRX in Q4 2016 and held it in 7 quarters. The position peaked at $10K in Q4 2016. 165 funds tracked by Wall St. Rank hold BCRX as of Q2 2020.

Meeder Asset Management reported no remaining BioCryst Pharmaceuticals position as of Q2 2020 after selling out during the quarter.
Meeder Asset Management sold 1,015 BioCryst Pharmaceuticals shares in Q2 2020, an estimated $2K.
Meeder Asset Management first reported a position in BioCryst Pharmaceuticals in Q4 2016 and held it in 7 quarters.
Meeder Asset Management's BioCryst Pharmaceuticals position peaked at $10K in Q4 2016.
165 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2020.

Based on Meeder Asset Management's 13F filing for Q2 2020, filed 11 Aug 2020.